Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » General » Unicorn Foundation exhibits at 12th Congress WFNMB

Unicorn Foundation exhibits at 12th Congress WFNMB

  • April 29, 2018

With the generosity and support of the organisers
of WFNMB, the Unicorn Foundation was amongst close to 150 exhibitors attended
by thousands of delegates from around the world. The program
encompassed the
multidisciplinary nature of the nuclear medicine profession and focused on high
level Continuing Education sessions over 13 tracks, outstanding plenary
speakers including two Nobel Laureates, leading expert faculty speakers
and opportunities for international networking with delegates from over 70
countries in the world.

The
congress was co-hosted by Australia New Zealand Society of Nuclear Medicine
(ANZSNM) many of which have a special interest in Neuroendocrine Tumors and are
great supporters of the Unicorn Foundation.

The
program included many NET related presentations including:

31I-MIBG Treatment in
Relapsed/Refractory Neuroblastoma

Dr Yoch Anongpornjossakul

Complementary Roles of Medical Oncologist and Nuclear Physician
in Clinical Practice of Theranostic Nuclear Oncology: Engagement and
Collaboration.

Prof J Harvey Turner
Prof Eva Segelov
Prof Richard P Baum
Prof Katherine Vallis
A/Prof Nat P Lenzo
Prof Francesco Giammarile

The Role of Somatostatin Analogues as a Combination with 177Lu-Octreotate
and Maintenance Therapy in Metastactic Neuroendocrine Tumours

Dr Anna Yordanova (Germany)

Intra-Arterial PRRT of Neuroendocrine Liver Metastases (NELM):
Experience in Over 50 Patients and Long Term Follow-up

Dr Aviral Singh

Saturday Plenary Session –
A Clinical Overview of Neuroendocrine Tumours
Dr David Chan

The Role of PET Imaging in Neuroendocrine Tumours
Dr Grace Kong

Theranostics of Neuroendocrine Neoplasms – Past, Present and
Future of PRRT

Dr Aviral Singh

What is “Theranostics” and How Will it Change the Role of
Nuclear Medicine Physicians in Patient-Care

Prof Rodney Hicks

New Challenges in Patient-specific Dosimetry of Therapy
Radipharmaceuticals (Pros)

Prof Michael Hofman

It
was also a great opportunity to promote the upcoming Asia Pacific
Neuroendocrine Tumor Society (APNETs) meeting which will also be held in Melbourne
at the Melbourne Exhibition and Convention Centre, November 9-11.

Thanks
again to the organisers of the WFNMB for supporting our attendance at this
fantastic meeting.

                           

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousMissing Unicorn on your Facebook Feed?
NextSydney Vital and STEaM Neuroendocrine Tumour PreceptorshipNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

NECA Christmas and New Year Closure Details

Neuroendocrine Cancer Australia advises holiday closure dates from Tuesday 24 December 2024 to Friday 3 January 2025. We will reopen on Monday 6 January 2025.

Sydney Unicorn Get Together 2024

On the eve of Neuroendocrine Cancer Day, we were thrilled to join in this special patient-organised event, celebrating a record turnout of nearly 50 patients,

Team Janine completes City2Surf and raises over $9,000 for NECA

Team Janine walked arm in arm in memory of NET Patient Janine during City2Surf this weekend. Many thanks to Melinda, Sally, Margie, Julie, Kate, Georgia,

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin